The contribution of glial inflammation in the pathogenesis of multiple sclerosis

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is one of the most prominent demyelinating disorders with a phenotype of relapsing and remitting neurological deficits. The recurrence of relapse contributes to the accumulation of neuronal damage, which leads to the transition of the disease into secondaryprogressive MS (SPMS). The mechanisms of SPMS are unknown, making the invention of new therapeutic options for SPMS difficult. In the progressive phase, "glial inflammation" is assumed to be the major player in neurodegeneration. Recently, our group and others have shown that gap junction proteins called connexins are important in the pathomechanisms of SPMS in the context of "glial inflammation". The expression of glia in connexins differs between cell types. Astroglial connexins are down regulated in the acute phase and up regulated in the chronic phase of MS, while oligodendroglial connexins are down regulated through the course of the disease. The modification and malfunction of gap junction connexins are thought to play roles in the pathomechanisms of SPMS. Further elucidation of their mechanisms may provide clues useful for the invention of new therapeutic options for SPMS.

Original languageEnglish
Pages (from-to)4-10
Number of pages7
JournalNeuro-Ophthalmology Japan
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Connexins
Neuroglia
Multiple Sclerosis
Inflammation
Recurrence
Gap Junctions
Demyelinating Diseases
Phenotype
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Clinical Neurology

Cite this

The contribution of glial inflammation in the pathogenesis of multiple sclerosis. / Yamasaki, Ryo; Kira, Jun Ichi.

In: Neuro-Ophthalmology Japan, Vol. 35, No. 1, 01.01.2018, p. 4-10.

Research output: Contribution to journalArticle

@article{e9deb70999844850ac7074e5ed7faf19,
title = "The contribution of glial inflammation in the pathogenesis of multiple sclerosis",
abstract = "Multiple sclerosis (MS) is one of the most prominent demyelinating disorders with a phenotype of relapsing and remitting neurological deficits. The recurrence of relapse contributes to the accumulation of neuronal damage, which leads to the transition of the disease into secondaryprogressive MS (SPMS). The mechanisms of SPMS are unknown, making the invention of new therapeutic options for SPMS difficult. In the progressive phase, {"}glial inflammation{"} is assumed to be the major player in neurodegeneration. Recently, our group and others have shown that gap junction proteins called connexins are important in the pathomechanisms of SPMS in the context of {"}glial inflammation{"}. The expression of glia in connexins differs between cell types. Astroglial connexins are down regulated in the acute phase and up regulated in the chronic phase of MS, while oligodendroglial connexins are down regulated through the course of the disease. The modification and malfunction of gap junction connexins are thought to play roles in the pathomechanisms of SPMS. Further elucidation of their mechanisms may provide clues useful for the invention of new therapeutic options for SPMS.",
author = "Ryo Yamasaki and Kira, {Jun Ichi}",
year = "2018",
month = "1",
day = "1",
doi = "10.11476/shinkeiganka.35.4",
language = "English",
volume = "35",
pages = "4--10",
journal = "Neuro-Ophthalmology Japan",
issn = "0289-7024",
publisher = "Neuro-Ophthalmology Society of Japan",
number = "1",

}

TY - JOUR

T1 - The contribution of glial inflammation in the pathogenesis of multiple sclerosis

AU - Yamasaki, Ryo

AU - Kira, Jun Ichi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Multiple sclerosis (MS) is one of the most prominent demyelinating disorders with a phenotype of relapsing and remitting neurological deficits. The recurrence of relapse contributes to the accumulation of neuronal damage, which leads to the transition of the disease into secondaryprogressive MS (SPMS). The mechanisms of SPMS are unknown, making the invention of new therapeutic options for SPMS difficult. In the progressive phase, "glial inflammation" is assumed to be the major player in neurodegeneration. Recently, our group and others have shown that gap junction proteins called connexins are important in the pathomechanisms of SPMS in the context of "glial inflammation". The expression of glia in connexins differs between cell types. Astroglial connexins are down regulated in the acute phase and up regulated in the chronic phase of MS, while oligodendroglial connexins are down regulated through the course of the disease. The modification and malfunction of gap junction connexins are thought to play roles in the pathomechanisms of SPMS. Further elucidation of their mechanisms may provide clues useful for the invention of new therapeutic options for SPMS.

AB - Multiple sclerosis (MS) is one of the most prominent demyelinating disorders with a phenotype of relapsing and remitting neurological deficits. The recurrence of relapse contributes to the accumulation of neuronal damage, which leads to the transition of the disease into secondaryprogressive MS (SPMS). The mechanisms of SPMS are unknown, making the invention of new therapeutic options for SPMS difficult. In the progressive phase, "glial inflammation" is assumed to be the major player in neurodegeneration. Recently, our group and others have shown that gap junction proteins called connexins are important in the pathomechanisms of SPMS in the context of "glial inflammation". The expression of glia in connexins differs between cell types. Astroglial connexins are down regulated in the acute phase and up regulated in the chronic phase of MS, while oligodendroglial connexins are down regulated through the course of the disease. The modification and malfunction of gap junction connexins are thought to play roles in the pathomechanisms of SPMS. Further elucidation of their mechanisms may provide clues useful for the invention of new therapeutic options for SPMS.

UR - http://www.scopus.com/inward/record.url?scp=85044992016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044992016&partnerID=8YFLogxK

U2 - 10.11476/shinkeiganka.35.4

DO - 10.11476/shinkeiganka.35.4

M3 - Article

AN - SCOPUS:85044992016

VL - 35

SP - 4

EP - 10

JO - Neuro-Ophthalmology Japan

JF - Neuro-Ophthalmology Japan

SN - 0289-7024

IS - 1

ER -